Aviza Technology, Inc. (NASDAQ: AVZA) 45% HIGHER; sees its Q1 sales at the low end of its previously issued guidance of $25-$32 million, which compares to the Street estimate of $26.20 million. At the same time, Aviza raised its Q1 adj-net income guidance from $50,000 to a loss of $4 million to a gain of $1-$4 million. Additionally, the company has decided to engage Needham & Company to explore partnering, financing and business development options.
Merix (Nasdaq: MERX) 23% LOWER; reports Q2 loss of $0.29, which may not compare to the analyst estimate of ($0.12). Revenue for the quarter
The Trading Radar highlights key earnings and economic announcements for tomorrow"s trading session:
Before Market Opens:
Economics:
8:30am ET
- Initial Jobless Claims for the week of 1/3 - Street expects 550K, compared to 492K last week
Earnings:
FCStone (Nasdaq: FCSX) - consensus loss $0.18, revs $75.20M
Helen of Troy (Nasdaq: HELE) - consensus EPS $0.75, revs $212.75M
PriceSmart (Nasdaq: PSMT)
RPM International (NYSE: RPM) - consensus EPS $0.35, revs $890.28M
Schnitzer Steel (Nasdaq: SCHN) - consensus loss $0.40, revs $421.89M
Shaw Group (NYSE: SGR) - consensus EPS $0.66, revs $1.91B
Intraday or Not Specified:
Economics:
2pm ET
- Consumer Credit for Nov. - Street expects up $0.5B, compared to down $3.5B in
Georgia Gulf Corp. (NYSE: GGC) 27.9% HIGHER; not hearing any news that would justify today"s large upside move on extremely heavy volume. Traders may be buying the stock on the back of strong earnings from Monsanto, as the two are both in the chemical manufacturing industry.
Netscout Systems (Nasdaq: NTCT) 27% HIGHER; sees Q3 EPS $0.24 to $0.26 versus consensus $0.13. Netscout Systems sees Q3 revenue of $73 million to $74 million versus consensus $64.62 million.
The McClatchy Company (NYSE: MNI) 22.8% LOWER; correcting today following 3 days of huge upside: since Thursday"s close, the stock was up 125%
StreetInsider.com Morning Movers:
La Jolla Pharmaceutical (Nasdaq: LJPC) 166% HIGHER; BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) and La Jolla have entered into an agreement to develop and commercialize Riquent, La Jolla"s investigational drug for lupus nephritis, in the United States, Europe and all other territories of the world, excluding the Asia Pacific region. Under the terms of the agreement, BioMarin will receive a co-exclusive license to develop and commercialize Riquent and La Jolla could receive up to $289 million in cash through milestones and equity purchases by BioMarin. Specific payments include: $15 million upfront, up to approximately $92.5 million related
UPGRADES:
Goldman Sachs upgrades AK Steel Holding Corp. (NYSE: AKS) from Neutral to Buy and added the stock to its Conviction Buy List. The firm also raised its price target on AK Steel from $9 to $15, which provides 34% upside from the current market price.
UBS upgrades Micron (NYSE: MU) from Neutral to Buy.
Goldman Sachs upgrades Northern Trust (Nasdaq: NTRS) from Neutral to Buy and raised its price target from $59 to $64.
For daily real-time Upgrades go to http://www.streetinsider.com/Upgrades
DOWNGRADES:
Deutsche Bank downgraded Las Vegas Sands (NYSE: LVS) today, from Buy to Hold, citing valuation and a shift in risk/reward.
- Satyam Computer Services Ltd. (NYSE: SAY) Co-Founder, Chairman B. Ramalinga Raju resigned today after admitting that he falsified earnings and assets.
A few week"s ago Satyam made a failed attempt to merge the company will two entities controlled by his family. He claimed it was an attempt to plug 50.4 billion rupees of "fictitious" cash of the company"s balance sheet.
He said profits have been inflated for "several years."
Shares of Satyam plunged in overseas trading on the news.
- Getinge AB today announced that it will extend its previously announced $53.00 per share cash tender offer for all of the outstanding shares of
|
|
News Center
